INDIGO: Obexelimab Cut IgG4-RD Flares — No Kidney-Specific Endpoints Reported

In the phase 3 INDIGO trial, weekly subcutaneous obexelimab reduced rescue-requiring flares and glucocorticoid rescue exposure versus placebo in active IgG4-related disease. The primary NEJM report does not include kidney-specific efficacy endpoints.

NephroResource

Taking longer than expected

If you're on a slow connection or this keeps happening, tap below to reload.